Symposium

What’s IL-23 Got to Do With It? Targeted Therapies in the Management of IBD

Launch Date
10/28/2024 at 07:30 pm EST
Credit Amount
1.5
Credit Expires
10/28/2024

Faculty

Marla Dubinsky, MD
Moderator
Professor of Pediatrics and Medicine 
Co-Director, Susan and Leonard Feinstein IBD Clinical Center 
Director, Marie and Barry Lipman IBD Preconception and Pregnancy Clinic 
Icahn School of Medicine Mount Sinai New York 
Chief, Division of Pediatric GI and Nutrition 
Mount Sinai Kravis Children’s Hospital
New York, NY
David P. Hudesman, MD, FACG, AGAF
Director, Inflammatory Bowel Disease Center at NYU Langone Health
Professor of Medicine, NYU Grossman School of Medicine
New York, NY
Corey A. Siegel, MD, MS
Director, Center for Digestive Health
Section Chief, Gastroenterology and Hepatology
Co-Director, Inflammatory Bowel Disease Center
Constantine and Joyce Hampers Professor of Medicine
Geisel School of Medicine at Dartmouth
Hanover, NH
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from a main source of production, namely CD64-positive myelocytes. As the treatment landscape of IL-23–targeted therapies continues to expand, it is crucial that gastroenterology clinicians understand the differentiating aspects of current and emerging treatments in order to develop an efficacious, lasting, and individualized treatment plan for each patient.

In this CME Outfitters live symposium, expert faculty will review the functions of Fc gamma receptors, CD64 and its connection with IL-23, the molecular attributes of anti–IL-23 therapies, in vivo data on expression of CD64 monocytes, and the most recent clinical trial data differentiating the anti–IL-23 agents. To demonstrate these concepts, animated 3-D models will be included in the educational program and available to attendees.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Assess the role of pro-inflammatory cytokines in driving inflammation in the pathogenesis of IBD
  • Classify the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis
  • Evaluate the clinical implications of anti–IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23–producing cells

Financial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies.

Target Audience

Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), and nurses

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.5

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

PAs (AAPA) 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 12/28/2024. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Dubinsky reports the following financial relationships:

Advisory Board and Consultant: AbbVie Inc.; Abivax; AstraZeneca; Bristol Myers Squibb Company; Celltrion Inc.; Janssen Biotech, Inc.; Lilly; Merck & Co., Inc; Pfizer Inc.; Prometheus Biosciences; Spyre Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Other financial or material support: (PI) Janssen Biotech, Inc. Road to Prevention; (Co-PI) Helmsley Foundation PK Dashboard Optimized Dosing of Infliximab Is Not Inferior to Standard Reactive Dosing: The OPTIMIZE Trial

Dr. Hudesman reports the following financial relationships:

Consultant: AbbVie Inc.; Avalo Therapeutics, Inc.; Bristol Myer Squibb Company; Eli Lily and Company; Fresenius Kabi; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus; and Takeda Pharmaceuticals U.S.A., Inc.

Research Support: Janssen Pharmaceuticals, Inc. and Pfizer Inc.

Dr. Siegel reports the following financial relationships:

Advisory Board: AbbVie Inc.; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Lilly; Napo Therapeutics; Pfizer Inc.; Prometheus Biosciences, Inc.; Roivant Sciences; Takeda Pharmaceuticals U.S.A., Inc.; and Trellus Health Inc.

Consultant: AbbVie Inc.; Boomerang; Bristol Myers Squibb Company; Buhlmann; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Prometheus Biosciences, Inc.; Prometheus Labs; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; and Pfizer Inc.

Other financial or material support: Dr. Corey Siegel is co-founder of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.

 

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MM-142-102824-01

What’s IL-23 Got to Do With It? Targeted Therapies in the Management of IBD
Event Date: 10/28/2024 at 07:30 pm EST
Register